Clinical trials
First-line Treatment clinical trials
Below are recruiting first-line treatment clinical trials, each written for real people, not researchers. We’re tracking 424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07485296RecruitingPhase 2
Postbiotics with pembrolizumab for advanced head and neck cancer
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
Rozzano, MilanoAges 18 years+ - NCT07493668RecruitingPhase 2
Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07528274RecruitingPhase 2
Microwave ablation with immunotherapy for advanced lung cancer
This trial tests combining microwave ablation (heat treatment of tumors) with two drugs—tislelizumab (an immune-boosting drug) and docetaxel (chemotherapy)—for patients with advanced non-small cell lung cancer whose disease progressed after initial immunotherapy. The goal is to see if this combination can slow or shrink tumors better than standard treatment alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT07669519RecruitingPhase 3
Supplement for fatigue in stage IV colon cancer
This study tests an oral supplement (Nuvastatic) to see if it helps reduce fatigue in people with stage IV colon cancer who are starting chemotherapy for the first time. If you are 18–65 and have fatigue that is affecting you, this trial might offer a way to feel better.
Srikakulam, Andhra PradeshAges 18–65 - NCT07670273RecruitingPhase 2
Drug combo for advanced HER2 bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
BeijingAges 18–75 - NCT07465497Enrolling by invitation
Preventing Chemo Brain with Prebiotics and Synbiotics
This trial tests whether taking a special blend of prebiotics and synbiotics (friendly bacteria and food for them) can help prevent or reduce memory and thinking problems that sometimes happen during chemotherapy for breast cancer.
Zapopan, JaliscoAges 18 years+ - NCT07258680Enrolling by invitationPhase 3
Testing brentuximab and etoposide for T-cell lymphoma
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Ages 18–70 - NCT06962449Enrolling by invitation
Study of Tislelizumab as First Treatment for Advanced Lung Cancer
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT06679803Enrolling by invitation
Physical activity help for stroke survivors
This study tests whether a physical activity program can help stroke survivors become more active after leaving the hospital. It may help you recover and feel better.
Minneapolis, MinnesotaAges 18 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06394674RecruitingPhase 2
High-dose furmonertinib for lung cancer after osimertinib stops working
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
ShanghaiAges 18–75 - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT04428554RecruitingPhase 2
Radiation to control bladder cancer spread after no growth
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
AlbiAges 18 years+ - NCT06447727Recruiting
Y-90 beads plus chemo for liver-only colorectal cancer
This trial tests whether adding radioactive Y-90 microspheres (tiny beads that deliver radiation directly to liver tumors) to standard chemo (FOLFIRI and bevacizumab) can help people with advanced colorectal cancer that has spread only to one lobe of the liver, when the first treatment stopped working. The goal is to slow down tumor growth.
Nanjing, JiangsuAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07276100RecruitingPhase 2
Fecal transplant to help liver cancer that worsened on first treatment
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
Bologna, BOAges 18 years+ - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Homewood, AlabamaAges 18 years+
Hear when a new First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line treatment?
- Yes. Clin2 currently lists 424 recruiting first-line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.